v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A preferred stock
Preferred Stock
Series A-2 preferred stock
Preferred Stock
Series A-3 preferred stock
Preferred Stock
Series CF preferred stock
Preferred Stock
Series B preferred stock
Common Stock
Additional Paid-in Capital
Subscription Receivable
Accumulated Deficit
Series A-3 preferred stock
Series CF preferred stock
Total
Beginning balance (in shares) at Dec. 31, 2019 20,714,518 5,654,072 5,932,742 8,223,036 126,641   664,167            
Beginning balance at Dec. 31, 2019 $ 2,071 $ 565 $ 593 $ 823 $ 12   $ 66 $ 15,486,050 $ (22,677) $ (22,617,702)     $ (7,150,199)
Issuance of Series CF preferred stock (in shares)         709,690                
Issuance of Series CF preferred stock         $ 71     309,679         $ 309,750
Issuance of Series A-3 preferred stock (in shares)       809,294             809,294 709,690 0
Issuance of Series A-3 preferred stock       $ 81       428,845 $ 22,677       $ 451,603
Issuance of Series B preferred stock (in shares)           20,754,717              
Issuance of Series B preferred stock           $ 2,075   10,997,925         11,000,000
Offering costs               (69,470)         (69,470)
Fair value of warrant issuances - venture debt               184,191         184,191
Stock-based compensation               144,775         144,775
Net loss                   (10,728,295)     (10,728,295)
Ending balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,481,995   (33,345,997)     (5,857,645)
Ending balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075) $ 403 5,888         6,291
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717) 4,027,181            
Issuance of common stock in public offering             $ 241 9,999,761         10,000,002
Issuance of common stock in public offering (in shares)             2,409,639            
Offering costs               (2,116,957)         (2,116,957)
Exercise of over-allotment option             $ 36 1,364,961         1,364,997
Exercise of over-allotment option (in shares)             361,445            
Conversion of debt into common stock             $ 114 2,680,175         2,680,289
Conversion of debt into common stock (in shares)             1,135,153            
Conversion of related party notes and payables into common stock             $ 15 257,500         257,515
Conversion of related party notes and payables into common stock (in shares)             152,357            
Common stock and warrants issued in connection with note             $ 13 501,645         501,658
Common stock and warrants issued in connection with note (in shares)             130,000            
Common stock issued in connection with business combination             $ 329 11,428,409         11,428,738
Common stock issued in connection with business combination (in shares)             3,294,309            
Exercise of warrants             $ 39 1,768,007         1,768,046
Exercise of warrants (in shares)             386,881            
Common stock issued pursuant to consulting agreement             $ 24 595,476         595,500
Common stock issued pursuant to consulting agreement (in shares)             241,459            
Stock-based compensation             $ 7 4,278,330         4,278,337
Stock-based compensation (Shares)             72,743            
Issuance of common stock pursuant to equity line of credit             $ 13 367,683         367,696
Issuance of common stock pursuant to equity line of credit (in shares)             126,356            
Net loss                   (32,357,957)     (32,357,957)
Ending balance at Dec. 31, 2021             $ 1,300 $ 58,612,873   $ (65,703,954)     $ (7,089,781)
Ending balance (in shares) at Dec. 31, 2021             13,001,690